Gilead Sciences (NASDAQ:GILD) Director Sells $356,670.66 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) Director Kelly Kramer sold 2,806 shares of the stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $127.11, for a total transaction of $356,670.66. Following the completion of the transaction, the director directly owned 1,339 shares of the company’s stock, valued at $170,200.29. The trade was a 67.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gilead Sciences Stock Up 0.9%

NASDAQ:GILD opened at $125.00 on Thursday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a market cap of $155.09 billion, a PE ratio of 19.38, a P/E/G ratio of 0.69 and a beta of 0.32. The company’s 50 day moving average is $120.53 and its two-hundred day moving average is $115.09.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s payout ratio is currently 48.99%.

Institutional Trading of Gilead Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Activest Wealth Management raised its position in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. GoalVest Advisory LLC increased its stake in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new position in Gilead Sciences in the 3rd quarter worth about $26,000. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the second quarter worth approximately $27,000. Finally, Putney Financial Group LLC grew its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on GILD shares. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Truist Financial assumed coverage on shares of Gilead Sciences in a research note on Monday, November 24th. They issued a “buy” rating and a $140.00 price objective on the stock. Finally, Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $130.65.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.